Keralam Health Minister K Muraleedharan on Friday defended the government’s decision to continue providing Natsmart, a lower-cost generic version of risdiplam manufactured by Indian pharmaceutical company Natco Pharma, to children suffering from spinal muscular atrophy (SMA).
Amid a controversy over medicine bottles carrying “Clinical Trial” and “Physician’s Sample” labels, the minister maintained that the drug was safe and that doctors had addressed parents’ concerns. He also suggested that a competing foreign pharmaceutical company could be behind the controversy.